{{{>>Moreover, Alpharma's action forced Pfizer to launch its own authorized generic, putting the drug giant in an awkward position in the pending patent litigation: How is Pfizer going to argue to the court that it would be irreparably harmed by a generic if it was putting one out itself?<<
I'm not sure I see the logic of the comment. Firstly, pfe's action (authorized generic) would have nothing to do with the patent validity. Maybe this could play a role in a damages phase?
Further, pfe certainly is going to lose hundreds of millions in lost revenues and profits because of this, so why not release a generic and try to recoup something? Should they be required to lose as much as possible to ALO?
It would take an awful lot to irreparably harm pfe!}}}
I just think that PFE launching an authorized generic copy is a de facto concession that the patent battle is over, and that generic competition will step up to the plate.
Market Data 
Markets 
AI
